The Gibco LV-MAX Lentiviral Production System is the first optimized system that provides a scalable and high-yield lentiviral vector production platform. It is based on a suspension, high-density culture of HEK 293-derived Viral Production Cells adapted to a special chemically defined, serum-free and protein-free LV-MAX Production Medium. Optimal viral titer yield is mediated by our advanced lipid nanoparticle transfection reagent in combination with a novel lentiviral-specific enhancer and supplement. All components work synergistically to generate superior and functional lentiviral particles under serum-free conditions compared to conventional polyethylenimine (PEI).
The LV-MAX Lentiviral Production System provides:
- High titer — Greater than 1 x 108 TU/mL (unconcentrated LVVs-GFP)
- Scalable suspension system — From 96 deep-well plate to 2-L bioreactor
- Serum-free — Eliminating animal-origin components and associated risks
- Easy, robust culture and transfection protocols — Fits into current transient production workflows